Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Salarius Pharmaceuticals (NASDAQ: SLRX) announced on Wednesday the initiation of the expansion of its ongoing 1-2 clinical trial of seclidemstat in patients with relapsed and refractory Ewing sarcoma and Ewing related sarcomas.
Seclidemstat is a reversal inhibitor of lysine-specific histone demethylase 1 enzyme that has been shown to play a critical role in the development and progression of certain cancers.
The expansion stage will consist of two treatment arms. The first arm will enrol up to 20 Ewing sarcoma patients and investigate the drug at the recommended Phase 2 dose. The second arm will enrol up to 30 patients with Ewing related sarcomas and study the drug as a single agent therapy.
Salarius expects to report data readouts from the trial towards the end of 2021 and into 2022.
“We believe our clinical program across Ewing and Ewing-related sarcomas allows more patients to receive seclidemstat far earlier in their treatment paradigm, and we believe this could not only increase the clinical benefits of seclidemstat but also provide the best chance to improve survival outcomes,” stated David Arthur president and CEO of Salarius Pharmaceuticals.
The company's shares are trading 19% higher at $2.30 at the time of writing.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .